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Beta-blocker efficacy across different
cardiovascular indications: an umbrella
review and meta-analytic assessment
Oliver J. Ziff1,2, Monica Samra2, James P. Howard3, Daniel I. Bromage2,4, Frank Ruschitzka5, Darrel P. Francis3 and
Dipak Kotecha1,6,7*
Abstract
Background: Beta-blockers are widely used for many cardiovascular conditions; however, their efficacy in
contemporary clinical practice remains uncertain.
Methods: We performed a prospectively designed, umbrella review of meta-analyses of randomised controlled
trials (RCTs) investigating the evidence of beta-blockers in the contemporary management of coronary artery
disease (CAD), heart failure (HF), patients undergoing surgery or hypertension (registration: PROSPERO
CRD42016038375). We searched MEDLINE, EMBASE and the Cochrane Library from inception until December 2018.
Outcomes were analysed as beta-blockers versus control for all-cause mortality, myocardial infarction (MI), incident
HF or stroke. Two independent investigators abstracted the data, assessed the quality of the evidence and rated the
certainty of evidence.
Results: We identified 98 meta-analyses, including 284 unique RCTs and 1,617,523 patient-years of follow-up. In
CAD, 12 meta-analyses (93 RCTs, 103,481 patients) showed that beta-blockers reduced mortality in analyses before
routine reperfusion, but there was a lack of benefit in contemporary studies where ≥ 50% of patients received
thrombolytics or intervention. Beta-blockers reduced incident MI at the expense of increased HF. In HF with
reduced ejection fraction, 34 meta-analyses (66 RCTs, 35,383 patients) demonstrated a reduction in mortality and HF
hospitalisation with beta-blockers in sinus rhythm, but not in atrial fibrillation. In patients undergoing surgery, 23
meta-analyses (89 RCTs, 19,211 patients) showed no effect of beta-blockers on mortality for cardiac surgery, but
increased mortality in non-cardiac surgery. In non-cardiac surgery, beta-blockers reduced MI after surgery but
increased the risk of stroke. In hypertension, 27 meta-analyses (36 RCTs, 260,549 patients) identified no benefit
versus placebo, but beta-blockers were inferior to other agents for preventing mortality and stroke.
Conclusions: Beta-blockers substantially reduce mortality in HF patients in sinus rhythm, but for other conditions,
clinicians need to weigh up both benefit and potential risk.
Keywords: Systematic review, Coronary artery disease, Heart failure, Hypertension, Perioperative, Meta-analysis,
Mortality, Myocardial infarction, Stroke
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Introduction
Beta-blockers are an established part of the routine man-
agement for many cardiovascular conditions and are widely
used by physicians across the spectrum of healthcare. They
act via multiple pathways, limiting the effects of catechol-
amine excess, affecting inotropy and chronotropy, provid-
ing anti-arrhythmic and anti-ischaemic effects and
inhibiting renin release. However, this diversity of action
carries the possibility of varying net effects on individual
outcomes, depending on patient characteristics and disease
substrate. Beta-blockers are well tolerated even in patients
with advanced conditions such as heart failure with reduced
ejection fraction (HFrEF), as confirmed in double-blind
randomised controlled trials (RCTs) [1]. Although side ef-
fects such as dizziness, lethargy and cold extremities are
commonly reported in clinical practice, similar rates are
seen with placebo [2]. Beta-blockers can cause bradycardia,
atrioventricular block and symptomatic hypotension, espe-
cially in patients with sinus and/or atrioventricular node
dysfunction [3], and are contraindicated in severe asthma
because of the risk of life-threatening bronchospasm [4].
The balance of risk versus benefit remains unclear in
many cardiovascular conditions. For example, in acute cor-
onary syndromes (ACS) and patients with coronary artery
disease (CAD), many RCTs predate reperfusion strategies
and contemporary medical treatment [5, 6]. There have
also been questions about the efficacy of beta-blockers in
HFrEF patients with concomitant atrial fibrillation [7] and
safety concerns for patients undergoing non-cardiac surgery
and in hypertension [8–10]. These uncertainties have con-
tributed to suboptimal uptake in patient groups where
beta-blockers are known to reduce mortality and morbidity.
Indeed, patients at greatest risk of death seem least likely to
receive evidence-based therapy [11, 12]. The aim of our
study was to review all available evidence for beta-blocker
therapy across these different cardiovascular indications,
providing clear assistance for clinicians and to inform fu-
ture guidelines. For each condition, we used an evidence-
based hierarchy that first identified the availability of indi-
vidual patient data (IPD) meta-analyses, and if not, whether
there were aggregate data meta-analyses with unbiased data
to better understand the balance of efficacy and safety of
beta-blockers.
Methods
Due to the comprehensive assessment, the main text fo-
cuses on the most robust findings with clinical impact;
all additional data are available in the Online Data Sup-
plement. The project was prospectively registered with
the PROSPERO database of systematic reviews
(CRD42016038375, [13]) and conducted according to
the Preferred Reporting Items for Systematic reviews
and Meta-Analyses (PRISMA) guidelines [14]. A system-
atic review of MEDLINE, EMBASE, the Cochrane
Library and other sources was performed (1960 to De-
cember 2018). Additional details on methodology are
presented in the Supplemental Methods.
Study selection
We included meta-analyses of RCTs that looked at the
clinical effects of beta-blockers on adults in four cardio-
vascular indications: CAD, heart failure, perioperative risk
reduction and hypertension. Definitions of cardiovascular
conditions and outcomes used by each individual meta-
analysis were accepted and are reported in Supplemental
Table 1. Administration of beta-blockers was via any route
versus control (placebo or no treatment). In the hyperten-
sion population, we also included meta-analyses compar-
ing beta-blockers with another active drug. Supplemental
Tables 1 and 2 provide details and references for all in-
cluded and excluded meta-analyses, respectively.
Data extraction
The predefined primary outcome was all-cause mortal-
ity. Secondary outcomes were cardiovascular mortality,
incident myocardial infarction (MI), heart failure and
stroke, as relevant to the cardiovascular indication.
Quality assessment
We employed an evidence-based hierarchy to determine
the quality of data. The first stage was the type of meta-
analysis, with IPD meta-analyses ranking first, and then
aggregate tabular data meta-analyses (herein simply re-
ferred to as meta-analyses). The second stage involved
careful exploration of study quality and potential bias
using AMSTAR (A Measurement Tool to Assess Multiple
Systematic Reviews) and ROBIS (Risk of Bias in System-
atic Reviews, Supplemental Table 3). The certainty of evi-
dence was evaluated using the GRADE (Grading of
Recommendations Assessment, Development and Evalu-
ation) approach and was classified as high, moderate, low
or very low (Supplemental Table 4 and using the GRADE-
proGDT software at gdt.gradepro.org/app/) [15].
Data synthesis and analysis
The outcome data from each meta-analysis was sum-
marised as a risk ratio (RR) using an intention-to-treat
approach and graphed in a forest plot. RR and associated
95% confidence intervals (CI) were calculated using the
published outcome data. These effect estimates were not
pooled, as many of the meta-analyses within the same
indication included the same trials; instead, we display
the range of confidence intervals and highlight the high-
est quality/lowest bias estimates of beta-blockers versus
control. Heterogeneity across trials is displayed as the I2
statistic. A two-tailed p value of 0.05 was considered sta-
tistically significant. Analyses were performed on Stata
version 14.1 (StataCorp LP, Texas).
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Results
We identified 98 meta-analyses suitable for quantitative
synthesis. These included 284 unique RCTs, with 418,
624 unique patients on beta-blocker therapy or control,
and 1,617,523 patient-years of follow-up (Supplemental
Figure 1). The risk of bias was variable in the meta-
analyses, but generally low (Supplemental Table 3 and
Supplemental Figure 2). There were notable exceptions,
including potential bias in data collection and study se-
lection in heart failure, and moderate overall risk of bias
in hypertension studies. Quality and risk of bias corre-
sponded to the robustness of the study design, with IPD
and prospectively registered meta-analyses demonstrat-
ing the highest quality and lowest risk of bias.
Coronary artery disease
There were no IPD studies and 12 other meta-analyses
meeting inclusion criteria, comprising 93 individual RCTs,
103,481 participants, mean follow-up of 7.8 months
(range: in-hospital to 6 years) and a total of 55,536 pa-
tient-years of follow-up. The RCTs were predominantly
historical, being performed before the routine use of re-
perfusion strategies; only 8 trials included patients where
≥ 50% of patients received thrombolytics or intervention.
A summary of the most contemporary data is presented
in Fig. 1 and detailed analysis in Supplemental Figure 3.
All-cause mortality
In studies before routine reperfusion, beta-blockers
reduced mortality compared to control in acute meta-
analyses (within 48 h of MI, RR range 0.83 to 0.98)
and non-acute meta-analyses (after 48 h, RR range
0.38 to 0.96). Where sub-group analyses were per-
formed to assess trials with routine reperfusion
(where ≥ 50% of patients received thrombolytics or
intervention), beta-blockers did not reduce mortality
either in the acute setting (12 RCTs, 48,806 partici-
pants; RR 0.98, 95% CI 0.92–1.04) or in non-acute
Fig. 1 Representative coronary artery disease meta-analyses.
Most up-to-date and highest quality meta-analyses for coronary artery disease. No individual patient data meta-analyses were available. Trials with
routine reperfusion had ≥ 50% of patients receiving thrombolytics or intervention. See Supplemental Figures 3 for full details. IHD, ischaemic
heart disease
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MI (2 RCTs, 1210 participants; RR 1.43, 95% CI
0.55–3.73).
Incident MI
In trials before routine reperfusion, beta-blockers re-
duced MI in both the acute setting (48 RCTs with 24,
773 participants; RR 0.76, 95% CI 0.61–0.94) and non-
acute setting (18 RCTs with 20,637; RR 0.77, 95% CI
0.69–0.86). Beta-blockers reduced incident MI in studies
with routine reperfusion only in the acute setting (12
RCTs with 48,274 participants, RR 0.72, 95% CI 0.62–
0.83; non-acute setting 2 RCTs with 1210 participants,
RR 0.75, 0.26–2.15).
Heart failure
In the acute setting, incident heart failure tended to be
more common with beta-blockers than control, but
this was only significant in trials with routine reperfu-
sion (9 RCTs with 47,272 participants; RR 1.10, 95% CI
1.05–1.16). Beta-blockers increased incident heart failure
in the non-acute setting in trials both before routine re-
perfusion (17 RCTs with 20,433 participants; RR 1.16,
95% CI 1.04–1.30) and with routine reperfusion (2 RCTs
with 1210 participants; RR 3.77, 95% CI 1.59–8.94).
Stroke
In both the acute and non-acute setting, beta-blockers
had no effect on incident stroke either before routine re-
perfusion (acute RR 2.96, 95% CI 0.47–18.81; non-acute
RR 1.54, 95% CI 0.60–3.95), or with routine reperfusion
(acute RR 1.09, 95% CI 0.91–1.30; non-acute RR 4.00,
95% CI 0.45–35.79).
Heart failure
Four IPD studies and 31 other meta-analyses met inclu-
sion criteria, comprising 66 individual RCTs, 35,383 par-
ticipants, mean follow-up of 12.3 months (range 3 to 32
months) and a total of 534,461 patient-years of follow-
up. The RCTs were predominantly in patients with
HFrEF; only 3 trials were designed to include patients
with left ventricular ejection fraction (LVEF) > 40%. A
summary of the highest quality data is presented in Fig. 2
and detailed analysis in Supplemental Figure 4.
All-cause mortality
IPD meta-analysis of 11 double-blind, placebo-
controlled RCTs demonstrated that beta-blockers signifi-
cantly reduced mortality in patients with sinus rhythm
(13,833 patients; RR 0.76, 95% CI 0.70–0.82), regardless
of age, gender or achieved heart rate. However, there
Fig. 2 Representative heart failure meta-analyses for all-cause mortality.
Most up-to-date and highest quality meta-analyses for heart failure. Results for other outcomes were similar to all-cause mortality. See
Supplemental Figure 4 for full details. ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; bpm, beats/min; CKD,
chronic kidney disease; HR, heart rate; LVEF, left ventricular ejection fraction
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was no reduction in mortality in the subgroups with
atrial fibrillation (3064 patients; RR 0.95, 0.83–1.10; pin-
teraction 0.002 for rhythm on baseline electrocardiogram)
[7], or the small subgroup with LVEF ≥ 50% [16]. In
non-IPD meta-analyses, beta-blockers were associated
with reduced mortality compared to control, but find-
ings were non-significant in subgroups with atrial fibril-
lation, LVEF > 40% and black patients, and inconsistent
in patients with diabetes.
Cardiovascular mortality, heart failure hospitalisation and
stroke
In both IPD and other meta-analyses, patients in (or pre-
dominantly in) HFrEF and sinus rhythm had substantial
reduction in cardiovascular mortality and heart failure
hospitalisation with beta-blockers compared to control.
Beta-blockers had no effect on non-fatal stroke com-
pared with placebo (16,644 patients) in patients in
HFrEF, irrespective of if they were in sinus rhythm (HR
1.02, 95% CI 0.78–1.32) or atrial fibrillation (HR 1.04,
95% CI 0.66–1.63).
Perioperative risk reduction
There were no IPD studies. Twenty-three other meta-
analyses with 89 individual RCTs were included, with
19,211 participants followed-up for a mean of 1 month
(range 24 h to 2 years; 1925 patient-years of follow-up).
A summary of representative data is presented in Fig. 3
and detailed analysis in Supplemental Figure 5.
All-cause mortality
In non-cardiac surgery, we saw a clear distinction in
treatment effect according to the risk of bias. In small
meta-analyses with high risk (that included the DE-
CREASE studies), there were reductions in mortality
with beta-blockers. Conversely, all large meta-analyses
with low risk of bias in non-cardiac surgery suggested
that beta-blockers increased mortality compared to con-
trol, ranging from RR 1.03 to 1.31. Meta-analyses in pa-
tients undergoing cardiac surgery showed no significant
effect of beta-blocker therapy.
Incident MI and stroke
Beta-blockers were consistently associated with a re-
duced risk of incident MI after non-cardiac surgery
(point estimate RR range 0.08 to 0.92), but an increased
risk of stroke (RR range 1.33 to 7.72). None of the meta-
analyses in cardiac surgery identified any significant dif-
ference with beta-blockers or control for either incident
MI or stroke.
Hypertension
There were no IPD studies and 28 other meta-
analyses, with 36 individual RCTs and 260,549 partici-
pants followed up for a mean of 3.7 years (range 1 to
10 years; 1,025,601 patient-years of follow-up). Sum-
mary findings are displayed in Fig. 4 and full analysis
in Supplemental Figure 6.
Fig. 3 Representative perioperative meta-analyses.
Highest quality meta-analyses of perioperative risk reduction using beta-blockers. No individual patient data meta-analyses were available. See
Supplemental Figure 5 for full details. The Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography (DECREASE) trials
II–VI were considered high risk of bias
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All-cause mortality
Mortality was not significantly different in any of 18
meta-analyses comparing beta-blockers with either
placebo or diuretics. Compared to renin-angiotensin
system (RAS) antagonists, all 5 meta-analyses demon-
strated a trend to increased mortality with beta-
blockers, ranging from RR 1.08 to 1.29, with diabetic
patients showing a significant increase. Compared to
CCB, all 3 meta-analyses demonstrated significantly
increased mortality with beta-blockers (RR range 1.07
to 1.11).
Incident MI and stroke
Across meta-analyses, there were no consistent differ-
ences in incident MI comparing beta-blockers with ei-
ther placebo or other therapy. Incident stroke rates were
significantly increased with beta-blockers versus either
RAS antagonists or CCB (representative RR 1.30 and
1.24, respectively), although not in diabetic patients.
Sensitivity analysis
There were no consistent differences between atenolol
and non-atenolol beta-blockers for the primary or sec-
ondary outcomes (Supplemental Figure 7).
Discussion
This umbrella review across cardiovascular indications
used meta-analytic data to clarify the evidence basis
for beta-blockers in contemporary clinical practice
(Table 1, Fig. 5). In patients with coronary disease,
there is a trade-off between benefit and risk. Beta-
blockers reduced the risk of incident MI at the ex-
pense of higher rates of incident HF, with no effect
on mortality. In patients with HFrEF in sinus rhythm,
beta-blockers reduced morbidity and mortality, but
they had no effect in HFrEF with concomitant atrial
fibrillation or those with preserved LVEF. In peri-
operative patients, although beta-blockers reduced the
risk of incident MI in those undergoing non-cardiac
surgery, this was at the expense of increased mortality
and stroke. Beta-blockers had no effect on any of the
outcomes assessed in patients undergoing cardiac sur-
gery. In hypertension, although beta-blockers had no
significant effect compared to placebo or diuretics,
they were inferior to RAS antagonists and CCB.
These findings highlight the importance of an indivi-
dualised assessment of indication, comorbidity and
understanding of the goal of therapy before routine
commencement of beta-blockers.
Fig. 4 Representative hypertension meta-analyses.
Highest quality meta-analyses of hypertension using beta-blockers. No individual patient data meta-analyses were available. See Supplemental
Figure 6 for full details. RAS, renin-angiotensin system; TIA, transient ischaemic attack
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Table 1 Evidence map of availability and appraisal of certainty of evidence for beta-blockers across cardiovascular indications
Certainty of evidence was assessed using the GRADE guidelines. See Supplemental Table 4 for full details. LVEF, left ventricular ejection fraction
Fig. 5 Overview of the evidence base for beta-blockers versus control in cardiovascular health.
a Compared to other medications. b In trials with a low risk of bias. c In contemporary trials with majority undergoing reperfusion. AF, atrial
fibrillation; CAD, coronary artery disease; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; MI, myocardial infarction; RR, risk ratio
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Coronary artery disease
Although beta-blockers were associated with reduction
in mortality in trials before routine reperfusion, the re-
duction in MI was offset by an increased risk of heart
failure. Although MI was a relatively rare event (absolute
event rate ~ 0.01%) and heart failure was more common
(absolute event rate ~ 13%), the number needed to treat
(NNT) to prevent an MI was 118 compared with the
number needed to harm (NNH) of 127 to cause an inci-
dent heart failure event. Additionally, before routine re-
perfusion, the event rate for mortality was 7.8% in
control versus 6.7% with beta-blockers (NNT 89) [6].
There were less tangible benefits in trials with routine
reperfusion where the majority of patients received re-
perfusion with either thrombolytics or coronary inter-
vention. In the International Study of Infarct Survival
(ISIS-1) trial in 1986, atenolol significantly reduced vas-
cular death, but only 5% of patients were on antiplatelet
agents [17]. In contrast, in the large Clopidogrel and
Metoprolol in Myocardial Infarction Trial (COMMIT)
published in 2005, metoprolol failed to reduce mortality
where all patients were on aspirin, 50% on dual anti-
platelet agents and 66% received thrombolysis [18]. The
combination of antiplatelet agents with prompt reperfu-
sion therapy in the modern era may restrict the extent
of myocardial damage in patients with MI and hence
limit the substrate which can benefit from sympathetic
inhibition and reduced myocardial oxygen demand.
The balance of benefit versus risk is particularly rele-
vant in acute MI where negative inotropy can lead to
cardiogenic shock. This may be more pertinent in larger
ST-elevation MI, where early high-dose beta-blockade
was associated with increased mortality [18]. In lower-
risk unstable angina patients, beta-blockers reduce the
risk of progression to acute MI [19]. Treatment duration
may be an important factor to achieve longer-term bene-
fit, but no RCTs directly investigated this issue. The
prognostic effects of beta-blockers in chronic stable is-
chaemic heart disease and stable angina without prior
MI remain unanswered. These issues all have important
relevance for future guidelines, particularly whether his-
torical data should be used to support contemporary
recommendations.
Heart failure
Beta-blockers have a class I, level of evidence A recom-
mendation in chronic HFrEF, and yet uptake in clinical
practice remains suboptimal in certain groups [20, 21].
Subgroup analyses have demonstrated that reduction of
mortality and hospitalisation with beta-blockers is con-
sistent in sinus rhythm, regardless of age or gender,
baseline heart rate or the degree of reduction in ejection
fraction [1, 16, 22]. However, IPD meta-analysis revealed
no signal for benefit in the subgroup of patients with
atrial fibrillation at baseline [7]. The reasons for this dis-
tinction remain unclear, but may relate to differences in
the association of heart rate and prognosis compared
with sinus rhythm [22], or consequences such as myo-
cardial fibrosis that may influence therapeutic efficacy
[23]. Heart failure with intermediate and preserved LVEF
accounts for over half of patients, and yet available data
is extremely limited [16]. Further RCTs are clearly war-
ranted to address this evidence gap, as well as the inter-
action with renal dysfunction which is common in
patients with HF [24].
Perioperative risk reduction
Beta-blockers are commonly considered to reduce the
risk of cardiovascular events in patients undergoing sur-
gery, but the controversy over integrity of data in the
DECREASE studies has led to questions about their true
value [25]. In meta-analyses with low risk of bias, we
saw an increase in mortality following non-cardiac sur-
gery compared with control and consistent increases in
stroke risk. These adverse events offset any benefit from
the reduced risk of MI and were consistent with the lar-
gest and highest quality individual RCT, the PeriOpera-
tive ISchemic Evaluation (POISE) trial [26]. However,
the frequency of mortality and incident stroke (absolute
event rates ~ 0.3% and ~ 0.6%, respectively) were rarer
than myocardial infarction (~ 4%). Indeed, the NNT to
prevent an MI was 72 compared with a NNH of 214 to
cause a death and 352 to cause a stroke [27]. In cardiac
surgery, where one might anticipate a prognostic benefit
from beta-blockers, we found no appreciable reduction
in events, including for incident MI.
Hypertension
Beta-blockers are no longer considered as a preferred
initial therapy for essential hypertension [9]. The chan-
ging approach and therapeutic options are further clari-
fied in the most recent guidelines [10]. However, many
patients still receive beta-blockers or continue therapy
from historical prescriptions [28]. Our analysis confirms
that beta-blockers are inferior to other agents (most not-
ably CCB and RAS antagonists), particularly in prevent-
ing strokes. This may be partly explained by differences
in achieved BP, including central systolic BP between
different drug treatments, to which cerebrovascular
events may be particularly sensitive. In addition, beta-
blockers are somewhat less effective than RAS antago-
nists and CCB in preventing target organ damage.
Importantly, beta-blockers are a heterogeneous class.
Whilst vasodilating beta-blockers, such as nebivolol, have
demonstrated favourable effects on central BP and cardio-
vascular surrogates, RCTs with these newer beta-blockers
in hypertensive patients are currently lacking. It is possible
that there are important differences between beta-
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blockers in efficacy and safety; however, there are insuffi-
cient data to be certain as atenolol was utilised in ~ 75%
of trials (our sensitivity analysis could only group together
‘non-atenolol’ studies). Although there remains a place for
beta-blockers in resistant hypertension or those with car-
diovascular comorbidities, our data would suggest that
physicians should be more aggressive in switching to alter-
native classes of anti-hypertensive medication.
Strengths and limitations
The strength of this analysis was the use of a systematic
and methodical approach to assess all published meta-
analyses of randomised trials across different cardiovas-
cular diseases. By focusing on the highest quality data
through a detailed risk of bias and quality assessment,
we were able to come to conclusions across various car-
diovascular conditions and subgroups. The trial popula-
tions were heterogeneous, but this provides results that
are more likely to represent clinical practice. It would
not have been feasible to assess all individual RCTs due
to the vast number included in our analysis. Our analysis
provides the most comprehensive and contemporary
summary of the efficacy of beta-blockers across cardio-
vascular diseases, thereby aiding physicians to initiate,
maintain or withdraw therapy in a patient group that
frequently has multi-morbidity and more than one clin-
ical indication.
As with all systematic reviews, we are limited by the
individual RCTs and the methodology of the component
meta-analyses. IPD has important advantages over ag-
gregate data meta-analysis, including the ability to im-
prove data quality and increase the precision of effect
size. Unfortunately, the series of IPD analyses from the
Beta-blockers in Heart Failure Collaborative Group [29]
were the only IPD studies available. Nevertheless, at least
for major outcomes, conventional meta-analysis can pro-
vide similar results and conclusions [30].
There are cardiovascular indications for beta-
blockers where data are extremely limited. Beta-
blockers are commonly used to control heart rate in
patients with atrial fibrillation; however, the evidence
base is extremely limited at present [31] and we iden-
tified no studies eligible for inclusion. Other cardiac
populations where beta-blockers are regularly pre-
scribed but where randomised trial evidence is limited
include chemotherapy toxicity, cardiomyopathies and
other arrhythmias (atrial and ventricular tachycardia).
There are also important and complex pharmacoki-
netic and pharmacodynamic differences between beta-
blocker subtypes, including lipid solubility, intravenous
versus oral administration routes, bioavailability and
first-pass metabolism variations. However, with the ex-
ception of hypertension, we were unable to assess het-
erogeneity of treatment effects between different beta-
blockers [32]. Finally, the trade-off between efficacy and
adverse events will vary according to individual patient
characteristics (cardiovascular condition, disease severity
and course, comorbidities, and coexisting therapies) and
beta-blocker effects (pharmacodynamics, receptor select-
ivity, dose and route of administration). All of these fac-
tors, and more, will impact on the clinical decision to
prescribe beta-blocker therapy.
Conclusions
Although beta-blockers are widely used in routine clin-
ical practice, this analysis indicates that their overall
clinical effect depends strongly on the clinical situation.
In patients with heart failure and reduced ejection frac-
tion who are in sinus rhythm, beta-blockers show clear
benefit in terms of mortality reduction and lower rates
of hospitalisation. However, beta-blockers show neutral
effects for many other clinical situations in the modern
era, and in some cases, harm.
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